Multiple cancer sites Cancer Malignant neoplasm without specification of site
Conditions
Interventions
Current information as of 12/07/2010:
Participants receive either a 100 µg, 200 µg, 300 µg selenium as selenium-enriched yeast supplement or a placebo yeast supplement every day for six months. Follow
Sponsors
Cancer Research UK (CRUK) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Volunteers aged 60 - 74 years old, either sex
Exclusion criteria
Exclusion criteria: Added 12/07/2010: 1. Southwest Oncology Group (SWOG) grading scale performance status score greater than 1 or equivalent 2. Active liver or kidney disease (known abnormal liver or kidney function) 3. Prior diagnosis of cancer (excluding non-melanoma skin cancer) 4. Diagnosed human immunodeficiency virus (HIV) infection 5. Diminished mental capacity (subjects must be able to give informed consent to participate as defined by ethics committees) 6. Taking 50 µg/day or more of selenium supplements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added 12/07/2010: This was a feasibility study to show the ability to run the main trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| Added 12/07/2010: 1. Mood (Profile of Mood States Bi-Polar Form [POMS-BI]), measured at baseline and 6 months 2. Quality of life (36-item Short Form Health Survey [SF-36]), measured at baseline and 6 months 3. Thyroid function (thyroid stimulating hormone [TSH], total and free T4 and T3), measured at baseline and six months | — |
Countries
United Kingdom
Outcome results
None listed